This 7% Yielding Healthcare Powerhouse Belongs in Retirees’ Portfolios

This 7% Yielding Healthcare Powerhouse Belongs in Retirees’ Portfolios Alex Sirois Tue, June 30, 2026 at 3:50 PM GMT+2 3 min read PFE NVDA Quick Read PFE's 7. 27% yield looks safe on a 53% adjusted payout ratio, but free cash flow fell short of dividends paid in 2025 by $690 million. Eleven directors acquired PFE phantom stock at $26.

67 on the same day, and CEO Albert Bourla bought shares six times in three months. Pfizer's 3. 26x net debt-to-EBITDA from the Seagen deal makes its $7.

2 billion cost savings target critical to keeping the dividend intact. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Pfizer didn't make the cut. Grab the names FREE today .

Few large-cap dividends generate as much skepticism as Pfizer ( NYSE:PFE ). The stock trades at $24. 37, and the COVID franchise erosion has been brutal, with Comirnaty down 59% and Paxlovid down 63% in Q1 2026.

Yet the dividend keeps coming. I want to know if that 7. 27% yield is a gift or a warning.

PeopleImages / Getty Images The Dividend at a Glance Pfizer's foundational portfolio in oncology, immunology, and cardiovascular care generates non-discretionary demand, and management recently declared its 351st consecutive quarterly payout. Metric Value Annual Dividend $1. 72 Dividend Yield 7.

27% Most Recent Increase $0. 42 to $0. 43 (Q1 2025) Aristocrat Status No (cut in 2009) Cash Flow Covers the Dividend, but Just Barely This is where I get cautious.

In 2025, operating cash flow was $11. 71 billion and capex was $2. 63 billion, leaving free cash flow of $9.

08 billion against $9. 77 billion in dividends paid. On adjusted earnings, however, the math looks better: full-year adjusted EPS of $3.

22 against $1. 72 in dividends works out to a 53% payout. Metric TTM Assessment Adjusted Earnings Payout 53% Healthy FCF Payout 108% Concerning OCF Coverage 1.

20x Adequate Leverage Is the Real Pressure Point Pfizer carries the Seagen acquisition debt, and it shows. Net debt-to-EBITDA sits at 3. 26x, elevated for a pharma major, while interest coverage of 5.

78x and debt-to-equity of 0. 78 leave room to service obligations. The $7.

2 billion cost savings target by end of 2027 matters because it directly defends the payout. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Pfizer didn't make the cut. Grab the names FREE today .

A Streak Reset by 2009, Rebuilt Since Pfizer cut from $0. 32 to $0. 16 quarterly in 2009 to fund the Wyeth deal.

Since 2010, the dividend has climbed every year, but recent raises are minimal. Year Annual Dividend 2026 $1. 72 2025 $1.

72 2024 $1. 68 2023 $1. 64 2022 $1.

60 Management and Insiders Are Putting Money Where the Mouth Is CEO Albert Bourla told investors in Q1 2026: "We're off to a strong start in 2026, and it reinforces our confidence that we will successfully navigate this defining period for Pfizer. " Backing that up, 11 directors simultaneously acquired phantom stock units on April 23, 2026 at $26. 67 per share, and Bourla himself added six times in three months.

Story Continues Verdict: Safe, but Watch the Cash Conversion Dividend Safety Rating: Safe. The earnings payout near 53% is comfortable, growth products like Eliquis, Padcev (+39%), and Vyndaqel (+8%) are scaling, and the Vyndamax patent now runs to June 2031. Pfizer fits an income-oriented thesis if the non-COVID portfolio offsets the $1.

5 billion biosimilar headwind. The safety case weakens if FCF coverage stays under 1. 0x for another full year, because management cannot lean on the balance sheet forever.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Pfizer didn't make the cut. Grab the names FREE today . Contact editorial@247wallst.

com for any questions or corrections.